160 related articles for article (PubMed ID: 9435190)
1. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation.
Felder CC; Joyce KE; Briley EM; Glass M; Mackie KP; Fahey KJ; Cullinan GJ; Hunden DC; Johnson DW; Chaney MO; Koppel GA; Brownstein M
J Pharmacol Exp Ther; 1998 Jan; 284(1):291-7. PubMed ID: 9435190
[TBL] [Abstract][Full Text] [Related]
2. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.
Rinaldi-Carmona M; Barth F; Millan J; Derocq JM; Casellas P; Congy C; Oustric D; Sarran M; Bouaboula M; Calandra B; Portier M; Shire D; Brelière JC; Le Fur GL
J Pharmacol Exp Ther; 1998 Feb; 284(2):644-50. PubMed ID: 9454810
[TBL] [Abstract][Full Text] [Related]
3. Characterization of two cloned human CB1 cannabinoid receptor isoforms.
Rinaldi-Carmona M; Calandra B; Shire D; Bouaboula M; Oustric D; Barth F; Casellas P; Ferrara P; Le Fur G
J Pharmacol Exp Ther; 1996 Aug; 278(2):871-8. PubMed ID: 8768742
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.
Schatz AR; Lee M; Condie RB; Pulaski JT; Kaminski NE
Toxicol Appl Pharmacol; 1997 Feb; 142(2):278-87. PubMed ID: 9070350
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
Showalter VM; Compton DR; Martin BR; Abood ME
J Pharmacol Exp Ther; 1996 Sep; 278(3):989-99. PubMed ID: 8819477
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1).
Hillard CJ; Manna S; Greenberg MJ; DiCamelli R; Ross RA; Stevenson LA; Murphy V; Pertwee RG; Campbell WB
J Pharmacol Exp Ther; 1999 Jun; 289(3):1427-33. PubMed ID: 10336536
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL
Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624
[TBL] [Abstract][Full Text] [Related]
8. Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase.
Rhee MH; Vogel Z; Barg J; Bayewitch M; Levy R; Hanus L; Breuer A; Mechoulam R
J Med Chem; 1997 Sep; 40(20):3228-33. PubMed ID: 9379442
[TBL] [Abstract][Full Text] [Related]
9. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor.
Glass M; Felder CC
J Neurosci; 1997 Jul; 17(14):5327-33. PubMed ID: 9204917
[TBL] [Abstract][Full Text] [Related]
10. SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist.
Portier M; Rinaldi-Carmona M; Pecceu F; Combes T; Poinot-Chazel C; Calandra B; Barth F; le Fur G; Casellas P
J Pharmacol Exp Ther; 1999 Feb; 288(2):582-9. PubMed ID: 9918562
[TBL] [Abstract][Full Text] [Related]
11. Differential CB1 and CB2 cannabinoid receptor-inotropic response of rat isolated atria: endogenous signal transduction pathways.
Sterin-Borda L; Del Zar CF; Borda E
Biochem Pharmacol; 2005 Jun; 69(12):1705-13. PubMed ID: 15885656
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid CB1 receptors fail to cause relaxation, but couple via Gi/Go to the inhibition of adenylyl cyclase in carotid artery smooth muscle.
Holland M; John Challiss RA; Standen NB; Boyle JP
Br J Pharmacol; 1999 Oct; 128(3):597-604. PubMed ID: 10516638
[TBL] [Abstract][Full Text] [Related]
13. Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling.
Tao Q; Abood ME
J Pharmacol Exp Ther; 1998 May; 285(2):651-8. PubMed ID: 9580609
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor.
Ruiu S; Pinna GA; Marchese G; Mussinu JM; Saba P; Tambaro S; Casti P; Vargiu R; Pani L
J Pharmacol Exp Ther; 2003 Jul; 306(1):363-70. PubMed ID: 12663689
[TBL] [Abstract][Full Text] [Related]
15. Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1.
Mo FM; Offertáler L; Kunos G
Eur J Pharmacol; 2004 Apr; 489(1-2):21-7. PubMed ID: 15063151
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the pharmacology of imidazolidinedione derivatives at cannabinoid CB1 and CB2 receptors.
Govaerts SJ; Muccioli GG; Hermans E; Lambert DM
Eur J Pharmacol; 2004 Jul; 495(1):43-53. PubMed ID: 15219819
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor.
Chen RZ; Frassetto A; Lao JZ; Huang RR; Xiao JC; Clements MJ; Walsh TF; Hale JJ; Wang J; Tong X; Fong TM
Eur J Pharmacol; 2008 Apr; 584(2-3):338-42. PubMed ID: 18336811
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
Rao GK; Kaminski NE
J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
[TBL] [Abstract][Full Text] [Related]
19. The pharmacology of cannabinoid receptors and their ligands: an overview.
Pertwee RG
Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S13-8. PubMed ID: 16570099
[TBL] [Abstract][Full Text] [Related]
20. Gi protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross-regulation.
Bouaboula M; Desnoyer N; Carayon P; Combes T; Casellas P
Mol Pharmacol; 1999 Mar; 55(3):473-80. PubMed ID: 10051530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
